Image Analysis Group, Resonance Health Formed Partnership
The companies combined clinical imaging technologies to enhance obesity and metabolic disease research.
Updated on Sept. 28, 2026 in Weight Loss
Live Poll
Do you believe partnerships between imaging companies improve clinical trial outcomes for new medical therapies?
Image Analysis Group and Resonance Health have entered a strategic partnership to integrate quantitative MRI capabilities with existing body-composition workflows. This collaboration focuses on supporting obesity and metabolic disease clinical trials by providing enhanced imaging data.
Why it matters
Clinical trial sponsors require precise data to differentiate reductions in adipose tissue from changes in lean and muscle mass. This partnership provides a comprehensive panel across imaging modalities to address these complex research needs.
The DYNAMIKA platform currently supports more than 700 clinical trials across a global network including the UK, EU, USA, India, China, and Australia. The partnership incorporates tools such as HepaFatScan to specifically assess liver fat levels.
The players
Image Analysis Group
An organization that provides DXA body-composition and muscle imaging workflows for clinical research.
Resonance Health
A company specializing in quantitative MRI capabilities, including liver and body-composition assessment tools.
The details
Image Analysis Group will incorporate Resonance Health's quantitative MRI endpoints into its clinical trial proposals. Resonance Health will gain access to the DYNAMIKA platform and its international reader network to standardize body-composition analysis.
Timeline
September 28, 2026: The partnership was announced.
The Big Picture
This partnership follows a pattern set by the DYNAMIKA platform to centralize complex imaging data for global clinical trials. By integrating MRI and DXA workflows, the companies aim to streamline how metabolic diseases are measured throughout clinical development phases.
This integration enables more accurate tracking of body fat and liver health during clinical studies for metabolic treatments. Improved imaging precision can accelerate the development and validation of new weight-loss therapies for patients.
The takeaway
Advancements in clinical imaging allow for a more nuanced understanding of how experimental treatments affect body composition beyond simple weight change. This improved precision is essential for developing effective long-term solutions for obesity and metabolic disorders.
Further reading
For more information on clinical research advancements, visit the Weight Loss section.
Source note: This article includes information reported by Scientist Live.
Live Poll
Do you believe partnerships between imaging companies improve clinical trial outcomes for new medical therapies?
